Immuno-Oncology Insights Magazine 2023; 4(3), 89–104 DOI: 10.18609/ioi.2022.013 Alloplex Commentary: SUPLEXA immunotherapeutic cells show promise in stabilizing metastatic cancer without adverse events in a Phase 1 trial, indicating potential as a personalized multi-cancer therapy.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
